275 related articles for article (PubMed ID: 106559)
41. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
42. Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.
Giacomini P; Veglia F; Cordiali Fei P; Rehle T; Natali PG; Ferrone S
Cancer Res; 1984 Mar; 44(3):1281-7. PubMed ID: 6692408
[TBL] [Abstract][Full Text] [Related]
43. [Study on cellular immunity and immunotherapy of malignant melanoma (author's transl)].
Ishihara K
Nihon Hifuka Gakkai Zasshi; 1975 Oct; 85(12):696-8. PubMed ID: 1238716
[No Abstract] [Full Text] [Related]
44. Immunobiology of human cutaneous melanoma.
Cochran AJ; Wen DR; Stene M; Fairhurst MV; Hoon DS
Prog Clin Biol Res; 1988; 256():597-618. PubMed ID: 3368501
[No Abstract] [Full Text] [Related]
45. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
46. [Clinical application of monoclonal antibodies to human malignant melanoma-associated antigens].
Kageshita T; Ishihara K
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1744-8. PubMed ID: 3899015
[TBL] [Abstract][Full Text] [Related]
47. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
Kristensen E
Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
[TBL] [Abstract][Full Text] [Related]
48. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
49. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
50. Characterization of surface antigens of transplantable melanomas in hamster on the basis of the macrophage migration inhibition test.
Kozłowska K; Zurawska-Czupa B; Kostulak A
Arch Immunol Ther Exp (Warsz); 1981; 29(1):137-42. PubMed ID: 7283676
[TBL] [Abstract][Full Text] [Related]
51. Human malignant melanoma cells: morphological and immunological variations.
Hakim AA
Neoplasma; 1977; 24(1):81-99. PubMed ID: 840339
[TBL] [Abstract][Full Text] [Related]
52. [Cutaneous, cellular immunity in malignant melanoma].
Kehrer HC
Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
[No Abstract] [Full Text] [Related]
53. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
54. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
55. Studies of humoral and cell-mediated immunity in human melanoma.
Mukherji B; Nathanson L; Clark DA
Yale J Biol Med; 1973 Dec; 46(5):681-92. PubMed ID: 4130586
[No Abstract] [Full Text] [Related]
56. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
57. [Cellular immunity in melanomalignome (author's transl)].
Fritz J; Grond K; Tilz GP
Arch Dermatol Res (1975); 1976 Apr; 255(2):203-9. PubMed ID: 1275554
[TBL] [Abstract][Full Text] [Related]
58. IgA as a blocking factor in human malignant melanoma.
O'Neill PA; Romsdahl MM
Immunol Commun; 1974; 3(5):427-38. PubMed ID: 4214759
[No Abstract] [Full Text] [Related]
59. Immunotherapy in patients with melanoma.
Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
[No Abstract] [Full Text] [Related]
60. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Vanwijck R; Bouillenne C; Malek-Mansour S
Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
